What is the difference between Davunetide and Vasopressin?

Davunetide: Stabilizes microtubules by interacting with tubulin and microtubule-associated proteins. Activates SIRT1, reduces amyloid-β toxicity, and enhances synaptic plasticity. Protects against tau hyperphosphorylation. Vasopressin: Neuropeptide binding V1aR (social behavior/memory, vasoconstriction), V1bR (ACTH/stress), V2R (antidiuretic); enhances hippocampal memory consolidation and social recognition

Is Davunetide FDA approved?

Davunetide is investigational and not FDA approved. It is discussed for research and educational purposes only, not as medical guidance.

Is Vasopressin FDA approved?

Vasopressin is FDA approved (FDA status current as of 2014-04-17). This regulatory status is provided for research and educational context only.

How is Davunetide administered in research settings?

In research settings, Davunetide is typically administered via the intranasal or subcutaneous routes. PeptideBase does not provide dosing or administration instructions.

How is Vasopressin administered in research settings?

In research settings, Vasopressin is typically administered via the intranasal, subcutaneous, or intravenous routes. PeptideBase does not provide dosing or administration instructions.

Home›Research›Compare›Davunetide vs Vasopressin

Peptide Comparison

Davunetide vs Vasopressin

Both are Neuro & Cognitive peptides.

Davunetide

NAP

CognitiveInvestigationalResearch Only

No providers listed yet

Full Davunetide profile →

Vasopressin

ADH

CognitiveFDA ApprovedPrescription

Half-life: 10-20 minutes

4 providers listed

Full Vasopressin profile →

Bottom line

Vasopressin is FDA-approved, while Davunetide is investigational — the clearest structural difference between them.

Quick Verdict

Davunetide

Evidence

Clinical

Half-life

—

Vasopressin

Evidence

Established Clinical

Half-life

10-20 minutes

Which One Should You Choose?

Your goal	Better option
Stronger clinical evidence	Vasopressin
Further along in FDA review	Vasopressin
More provider options (0 vs 4)	Vasopressin

Research summary only — not medical advice. Consult a qualified provider before making any decisions.

Side-by-Side Comparison

Davunetide

Vasopressin

Mechanism Family

Neuro & Cognitive

Half-life

—

10-20 minutes

FDA Status

investigational

approved

Admin Routes

intranasal, subcutaneous

intranasal, subcutaneous, intravenous

Availability

Research Only

Prescription

Providers

None listed

4 listed

FDA Update

—

Apr 2014

Avail. Notes

—

FDA-approved vasopressin injection. Brand: Vasostrict (NDA 204485, Apr 2014). Indicated for vasodilatory shock. As an FDA-approved drug with a USP monograph, it is compounded via the approved-drug / monograph route rather than the 503A bulk-substances list. Prescription only.

Research Evidence

Davunetide

ClinicalRCT · 3 key studies · most recent 2026

Vasopressin

Established ClinicalMeta-analysis · 13 key studies · most recent 2026

Research Citations

Davunetide

Cohort2026 · Epilepsy Res

Microtubule-stabilizing drugs suppress convulsions in a C. elegans model of CAMSAP disorders.

RCT2013 · Neuropsychopharmacology

Effects of davunetide on N-acetylaspartate and choline in dorsolateral prefrontal cortex in patients with sch…

RCT2011 · Schizophrenia Research

Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophren…

Vasopressin

Meta-analysis2026 · Front Endocrinol (Lausanne)

The hypothalamic-neurohypophyseal system in preeclampsia: a systematic review with a subgroup meta-analysis o…

Meta-analysis2026 · Front Endocrinol (Lausanne)

The hypothalamic-neurohypophyseal system in preeclampsia: a systematic review with a subgroup meta-analysis o…

Cohort2026 · Sci Rep

Effects of septic shock vasopressors on the fitness of Escherichia coli.

Cohort2026 · Prog Neurobiol

Tracing the impact of electrophysiological studies of magnocellular neurons.

+9 more

About Davunetide

Stabilizes microtubules by interacting with tubulin and microtubule-associated proteins. Activates SIRT1, reduces amyloid-β toxicity, and enhances synaptic plasticity. Protects against tau hyperphosphorylation.

Research Areas

neuroprotectiontau stabilizationcognitive enhancementmemorysynaptic plasticity

About Vasopressin

Neuropeptide binding V1aR (social behavior/memory, vasoconstriction), V1bR (ACTH/stress), V2R (antidiuretic); enhances hippocampal memory consolidation and social recognition

Research Areas

memory consolidationsocial memoryfluid retentionvasoconstriction

Safety Profile

Information below reflects published research data only — not medical advice. Consult a qualified provider before use.

Davunetide

No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.

Vasopressin

Reported (Unverified — Pending Clinical Review)

hypertensioncoronary artery diseasehyponatremia riskheart failure

No established clinical contraindications

Suggested Monitoring

Under clinical review

Being verified by our medical team before we display monitoring guidance for this peptide.

Find Providers

Where to source these peptides

Providers offering

Davunetide

Browse directory →

Providers offering

Vasopressin

4 listed

Browse directory →

PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.

More Neuro & Cognitive Comparisons

Browse all peptides →

Educational research tools — not medical advice.